PMID- 35710921
OWN - NLM
STAT- MEDLINE
DCOM- 20220620
LR  - 20220817
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jun 16
TI  - Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes 
      mellitus and causes of death analysis.
PG  - 10147
LID - 10.1038/s41598-022-13760-7 [doi]
LID - 10147
AB  - Sodium-glucose cotransporter 2 inhibitor (SGLT2i) potentially decrease all-cause 
      and cardiovascular death, however, associations with non-cardiovascular death 
      remain unclear. Therefore, we investigated SGLT2i associations with death and the 
      cause of death. We used the Taiwanese National Health Institutes Research 
      database linked to the National Register of Deaths (NRD). Incident type 2 
      diabetes mellitus (T2DM) patients and propensity score matched T2DM SGLT2i and 
      Dipeptidyl peptidase 4 inhibitor (DPP4i) users were investigated. The index year 
      was the SGLT2i or DPP4i prescription date from May 2016. Patients were 
      followed-up until death or December 2018. Deaths verified by the NRD and grouped 
      accordingly. Multiple Cox proportional hazards models were used. In total, 
      261,211 patients were included in the population; 47% of the patients were female 
      and the average age was 62 years. The overall incidence of all-cause death was 
      8.67/1000 patient-years for SGLT2i and 12.41 for DPP4i users during follow-up. 
      After adjusting for potential risk factors in the propensity score matched 
      population, SGLT2i users were associated with lower risks of all-cause death, 
      cardiovascular death, cancer death, and non-cancer, non-vascular death compared 
      with DPP4i-users. For specific death causes, significantly lower death risks from 
      heart disease, cerebrovascular disease, and accidents were associated with 
      SGLT2i-use. SGLT2i benefits for T2DM patients were not different across 
      subgroups. Compared with DPP4i-use, SGLT2i-use for T2DM was associated with lower 
      disease and death risk.
CI  - (c) 2022. The Author(s).
FAU - Chung, Mu-Chi
AU  - Chung MC
AD  - Division of Nephrology, Department of Medicine, Taichung Veterans General 
      Hospital, Taichung, Taiwan.
AD  - Ph.D. Program in Translational Medicine, National Chung Hsing University, 
      Taichung, Taiwan.
AD  - Rong Hsing Research Center for Translational Medicine, National Chung Hsing 
      University, Taichung, Taiwan.
AD  - Department of Biotechnology, Asia University, Taichung, Taiwan.
FAU - Hsu, Hui-Tsung
AU  - Hsu HT
AD  - Department of Public Health, College of Public Health, China Medical University, 
      No. 100, Sec. 1, Jingmao Rd., Beitun Dist., Taichung City, 406040, Taiwan.
FAU - Chang, Chao-Hsiang
AU  - Chang CH
AD  - Department of Urology, China Medical University and Hospital, Taichung, Taiwan.
FAU - Hung, Peir-Haur
AU  - Hung PH
AD  - Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian 
      Hospital, Chiayi, Taiwan.
AD  - Department of Applied Life Science and Health, Chia-Nan University of Pharmacy 
      and Science, Tainan, Taiwan.
FAU - Hsiao, Po-Jen
AU  - Hsiao PJ
AD  - Department of Urology, China Medical University and Hospital, Taichung, Taiwan.
FAU - Wu, Laing-You
AU  - Wu LY
AD  - Department of Public Health, College of Public Health, China Medical University, 
      No. 100, Sec. 1, Jingmao Rd., Beitun Dist., Taichung City, 406040, Taiwan.
FAU - Wu, Ming-Ju
AU  - Wu MJ
AD  - Division of Nephrology, Department of Medicine, Taichung Veterans General 
      Hospital, Taichung, Taiwan.
FAU - Shieh, Jeng-Jer
AU  - Shieh JJ
AD  - Rong Hsing Research Center for Translational Medicine, National Chung Hsing 
      University, Taichung, Taiwan.
AD  - Institute of Biomedical Sciences, National Chung Hsing University, Taichung, 
      Taiwan.
AD  - Department of Education and Research, Taichung Veterans General Hospital, 
      Taichung, Taiwan.
FAU - Chung, Chi-Jung
AU  - Chung CJ
AD  - Department of Public Health, College of Public Health, China Medical University, 
      No. 100, Sec. 1, Jingmao Rd., Beitun Dist., Taichung City, 406040, Taiwan. 
      cjchung@mail.cmu.edu.tw.
AD  - Department of Medical Research, China Medical University Hospital, Taichung, 
      Taiwan. cjchung@mail.cmu.edu.tw.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220616
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cause of Death
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Dipeptidyl-Peptidase IV Inhibitors/pharmacology
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology
PMC - PMC9203810
COIS- The authors declare no competing interests.
EDAT- 2022/06/18 06:00
MHDA- 2022/06/22 06:00
PMCR- 2022/06/16
CRDT- 2022/06/17 00:20
PHST- 2022/03/25 00:00 [received]
PHST- 2022/05/27 00:00 [accepted]
PHST- 2022/06/17 00:20 [entrez]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/06/16 00:00 [pmc-release]
AID - 10.1038/s41598-022-13760-7 [pii]
AID - 13760 [pii]
AID - 10.1038/s41598-022-13760-7 [doi]
PST - epublish
SO  - Sci Rep. 2022 Jun 16;12(1):10147. doi: 10.1038/s41598-022-13760-7.